Physician profile
Christopher Simpson
NPI 1811931090
$2,332.52
in general payments reported to CMS, 2019-2025
21 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $133 · 2021: $272 · 2022: $393 · 2023: $482 · 2024: $250 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.44 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $649.31 | 2019-2025 | Xience Skypoint, Amplatzer Amulet, Assurity |
| Medtronic, INC. | $400.00 | 2021-2024 | Cobalt Dr Mri Surescan, Micra, Linq II |
| Abiomed | $307.96 | 2019-2023 | Impella |
| Amgen INC. | $209.46 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $140.47 | 2021-2023 | |
| Medtronic Vascular, INC. | $110.36 | 2019-2020 | |
| Philips North America LLC | $69.70 | 2019 | |
| Heartflow, INC. | $63.75 | 2022 | |
| Baxter Healthcare | $62.36 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $50.20 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $40.75 | 2023-2024 | Xarelto |
| Amarin Pharma, INC. | $36.58 | 2020-2022 | |
| Atricure, INC. | $31.05 | 2019 | |
| Pfizer INC. | $30.25 | 2019-2022 | |
| Biotronik INC. | $23.72 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22.81 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $21.35 | 2021 | |
| Boston Scientific Corporation | $18.72 | 2025 | Ranger |
| Elutia, INC. | $17.28 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.